SK Biopharmaceuticals (KRX:326030) Full Year 2024 Results
Key Financial Results
- Revenue: ₩547.6b (up 54% from FY 2023).
- Net income: ₩240.7b (up from ₩32.9b loss in FY 2023).
- Profit margin: 44% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue.
- EPS: ₩3,074 (up from ₩420 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
SK Biopharmaceuticals Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) also surpassed analyst estimates significantly.
Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in South Korea.
Performance of the South Korean Pharmaceuticals industry.
The company's shares are down 8.8% from a week ago.
Risk Analysis
It is worth noting though that we have found 1 warning sign for SK Biopharmaceuticals that you need to take into consideration.
If you're looking to trade SK Biopharmaceuticals, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSE:A326030
SK Biopharmaceuticals
A pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders.
Flawless balance sheet with reasonable growth potential.
